Consensus guidelines for the management and treatment of neuroendocrine tumors

Pancreas

Volumn 42, Issue 4, 2013, Pages 557-577

  Kunz, Pamela L ^a   Reidy Lagunes, Diane ^b   Anthony, Lowell B ^c   Bertino, Erin M ^d   Brendtro, Kari ^e   Chan, Jennifer A ^f   Chen, Herbert ^g   Jensen, Robert T ^h   Kim, Michelle Kang ⁱ   Klimstra, David S ^b   Kulke, Matthew H ^f   Liu, Eric H ^j   Metz, David C ^k   Phan, Alexandria T ^l   Sippel, Rebecca S ^g   Strosberg, Jonathan R ^m   Yao, James C ⁿ  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^d THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^e NANETS and NET Patient Advocate   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^h NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

ⁱ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^j VANDERBILT UNIVERSITY   (United States)

^k UNIVERSITY OF PENNSYLVANIA   (United States)

^l UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^m H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁿ UNIVERSITY OF TEXAS   (United States)

more..

Author keywords

carcinoid; neuroendocrine tumors; neuroendocrine diagnosis; neuroendocrine pathology; neuroendocrine treatment; pheochromocytoma

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; CHROMOGRANIN A; CORTICOTROPIN; DEXAMETHASONE; DIAZOXIDE; EVEROLIMUS; OCTREOTIDE; PENTETREOTIDE IN 111; PROTON PUMP INHIBITOR; SUNITINIB;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER SCINTISCANNING; CANCER SURVIVAL; CARCINOID SYNDROME; DRUG EFFICACY; ENDOSCOPIC SURGERY; FOLLOW UP; GASTRINOMA; HEMICOLECTOMY; HUMAN; IMMUNOHISTOCHEMISTRY; INSULINOMA; LYMPH NODE DISSECTION; MITOSIS RATE; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PANCREATICODUODENECTOMY; PHASE 3 CLINICAL TRIAL (TOPIC); PHEOCHROMOCYTOMA; PRACTICE GUIDELINE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEROID THERAPY; TUMOR BIOPSY;

HUMANS; MOLECULAR TARGETED THERAPY; NEUROENDOCRINE TUMORS; NORTH AMERICA; SOCIETIES, MEDICAL; TUMOR MARKERS, BIOLOGICAL;

EID: 84876840005     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31828e34a4     Document Type: Article

References (21)

1. Anthony LB, Strosberg JR, Klimstra DS, et al. The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (nets): Well-differentiated nets of the distal colon and rectum. Pancreas. 2010; 39(6): 767-774.
2. Boudreaux JP, Klimstra DS, Hassan MM, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: Well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. Pancreas. 2010; 39(6): 753-766.
3. Chen H, Sippel RS, O'Dorisio MS, et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: Pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010; 39(6): 775-783.
4. Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors: A review of nomenclature, grading, and staging systems. Pancreas. 2010; 39(6): 707-712.
5. Kulke MH, Anthony LB, Bushnell DL, et al. NANETS treatment guidelines: Well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010; 39(6): 735-752.
6. Phan AT, Oberg K, Choi J, et al. NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: Well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas. 2010; 39(6): 784-798.
7. Strosberg JR, Coppola D, Klimstra DS, et al. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas. 2010; 39(6): 799-800.
8. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364(6): 514-523.
9. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364(6): 501-513.
10. Klimstra DS, Modlin IR, Adsay NV, et al. Pathology reporting of neuroendocrine tumors: Application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol. 2010; 34(3): 300-313.
11. Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study. Lancet. 2011; 378(9808): 2005-2012.
12. Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011; 117(2): 268-275.
13. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J Clin Oncol. 2009; 27(28): 4656-4663.
14. Yao JC, Pavel M, Phan AT, et al. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab. 2011; 96(12): 3741-3749.
15. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: Toxicity, efficacy, and survival. J Clin Oncol. 2008; 26(13): 2124-2130.
16. Madoff DC, Gupta S, Ahrar K, et al. Update on the management of neuroendocrine hepatic metastases. J Vasc Interv Radiol. 2006; 17(8): 1235-1249; quiz 1250.
17. Reidy DL, Tang LH, Saltz LB. Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors. Nat Clin Pract Oncol. 2009; 6(3): 143-152.
18. Schurr P, Strate T, Rese K, et al. Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: An institutional experience. Ann Surg. 2007; 245(2): 273-281.
19. Touzios J, Kiely J, Pitt S, et al. Neuroendocrine hepatic metastases: Does aggressive management improve survival? Ann Surg. 2005; 241(5): 776-783.
20. Sarmiento J, Heywood G, Rubin J. Surgical treatment of neuroendocrine metastases to the liver: A plea for resection to increase survival. J Am Coll Surg. 2003; 197: 29-37.
21. Chamberlain R, Canes D, Brown K, et al. Hepatic neuroendocrine metastases: Does intervention affect outcome? J Am Coll Surg. 2000; 190: 432-445.